Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells

Although multitargeted tyrosine kinase inhibitor sunitinib has been used as first‐line therapeutic agent against metastatic renal cell carcinoma (mRCC), the molecular mechanism and functional role per se for its therapeutic performance remains obscure. Our present study revealed that sunitinib‐treat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Zhu, Yu, Xu, Le, Zhang, Jianping, Hu, Xiaoyi, Liu, Yujun, Yin, Hankun, Lv, Tao, Zhang, Heng, Liu, Li, An, Huimin, Liu, Haiou, Xu, Jiejie, Lin, Zongming
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2013
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657144/
https://ncbi.nlm.nih.gov/pubmed/23578198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12176
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars